ZYBERNO
Stock Report
Updated Aug 24, 2026

RELIEF THERAPEUTICS HOLDING SA (RLFTF)

Healthcare • OTC

$0.27

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
19.0/100
POOR BUSINESS
RELIEF THERAPEUTICS HOLDING SA (RLFTF) scores 19/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.01x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-218.6%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

RELIEF THERAPEUTICS HOLDING SA (RLFTF) stock report — Zyberno Score 19/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.27
Market Cap:$38.72M

Valuation Multiples (3)

P/B Ratio:0.60x
P/S Ratio:4.95x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$21.15M

Price Action & Momentum (3)

Momentum Percentile:1 / 100
% of 52-Week High:8.9%
B. Profitability Assessment

Return Metrics (3)

Reinvestment Rate:3.5%
Fundamental Growth Rate (g):-7.6%

Margin Analysis (1)

Ebitda Margin:-1,699.0%

Yield Metrics (2)

Earnings Yield:-$999.00
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:2.65x
Quick Ratio:2.57x
Cash Ratio:2.11x

Leverage Analysis (3)

Debt To Equity Ttm:0.01x
Debt-to-Equity Ratio:0.01x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-116.78x
Times Interest Earned:-116.78

Capital Structure (4)

Working Capital:14,088,584.29
Cash And Cash Equivalents:17,996,790.95
Long Term Debt:$11.13K
Net Debt:-$17.57M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$7.82M
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$137.03M

Bottom Line Performance (3)

-$121.39M
Income Before Tax:$0.00
Ebitda Ttm:-132,923,536.33

Operating Expenses (5)

Operating Expenses:0.00
R And D Expense:0.00
Sga Expense:0.00
Income Tax Expense:-$16.69M
Interest Expense:1,173,327.47

Expense Ratios (3)

R And D To Revenue Percentage:0.0%
Sga To Revenue Percentage:0.0%
Ebitda Margin:-1,699.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$94.45M
Current Assets:$22.63M
Ppe Net:490,844.05
Goodwill:0.00
Intangible Assets:$67.28M

Liability Structure (4)

Total Liabilities:29,873,486.05
Current Liabilities:8,542,170.15
Long Term Debt:$11.13K
Short Term Debt:$416.66K

Equity & Capital (3)

Equity:$64.57M
Retained Earnings:$0.00
Common Stock:0.00

Working Capital Items (3)

Accounts Receivable:1,447,804.49
Inventory:688,665.33
Accounts Payable:1,267,292.58

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:0.00
C. Cash Flow Analysis

Operating Activities (2)

-$21.78M-$22.33M

Investment Activities (1)

Investing Cash Flow:$10.75M

Financing Activities (3)

Financing Cash Flow:$5.01M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (1)

Earnings Per Share Ttm:-$0.83

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.05
Operating Cash Flow Per Share:-$0.15

Book Value & Capital (2)

Book Value Per Share:$0.44
Cash Per Share:0.12

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.08x
Working Capital Turnover Ttm:0.56x

Receivables Management (2)

Receivables Turnover Ttm:5.40x
Days Sales Outstanding Ttm:67.54

Inventory Management (2)

Inventory Turnover Ttm:11.36x
Days Inventory Outstanding Ttm:32.13

Payables & Cash Cycle (2)

Days Payable Outstanding:59.12
Cash Conversion Cycle:40.55
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:40.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:3.5%
Fundamental Growth Rate (g):-7.6%
B. Log-Linear Regression Growth Analysis
C. Company Profile & Context

Corporate Information (6)

Symbol:RLFTF
Company Name:RELIEF THERAPEUTICS HOLDING SA
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:OTC
Country:Unknown

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:146.13M
Shares Outstanding Basic:0
Shares Outstanding Diluted:0

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-24 11:10:45 UTC
Data Timestamp:2026-08-24T10:56:31.943895
Scroll to Top